Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum

P. J M Riviere, R. K. Rao, X. Pascaud, J. L. Junien, Frank Porreca

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The effects of putative σ ligands and two neuropeptides on intestinal ion transport were evaluated in isolated sheets of whole mouse jejunum mounted in Ussing flux chambers. Serosal administration of neuropeptide Y (NPY), peptide YY (PYY), (+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1- ylamine hydrochloride (JO 1784), di(ortho-tolyl) guanidine (DTG) and (+)- or (-)-N-allyl-normetazocine (NANM) produced concentration-related decreases in short-circuit current (I(sc)) without changes in tissue conductance. Although NPY and PYY were active in nanomolar concentrations, JO 1784, DTG and (+)- and (-)-NANM were active in micromolar concentrations; the rank order of potency in inhibiting I(sc) was PYY > NPY >> JO 1784 = (-)-N- cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1-ylamine hydrochloride > DTG > (+)-NANM = (-)-NANM. Serosal application of tetrodotoxin effectively blocked the decrease in I(sc) associated with all of the ligands tested. The activity of the serosally applied ligands was blocked by prior application of chlorisondamine, a ganglionic blocker. The effects of JO 1784 and NPY were evaluated using antagonists of several receptor types. Although application of serosal haloperidol had no effect alone up to concentrations of 1 μM, this compound produced a rightward displacement in both the NPY and JO 1784 concentration-effect curves. In contrast, sulpiride, SCH-23390, naloxone, yohimbine and prazosin failed to antagonize the effects of NPY or JO 1784. Application of NPY and JO 1784 on the mucosal side of intact jejunum showed that both compounds maintained activity, though the potency of each was considerably reduced compared to serosal administration. Finally, the activity of both NPY and JO 1784 was greatly reduced in a jejunal preparation physically stripped of the enteric ganglia and muscularis externa (i.e., mucosal preparation). The data indicate that putative σ ligands and NPY and PYY produce a concentration-related and haloperidol- sensitive reduction in I(sc), which is mediated via actions on nerves, and that these effects are mediated mainly through preganglionic sites. Furthermore, the insensitivity of the responses of JO 1784 and NPY to antagonists at opioid, dopaminergic or adrenergic receptors suggests that the effects of NPY and JO 1784 may be associated with a putative σ site. These data suggest that a novel application of potential therapeutic interest will be the development of σ ligands for the investigation and treatment of gastrointestinal disorders.

Original languageEnglish (US)
Pages (from-to)1268-1274
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume264
Issue number3
StatePublished - 1993

Fingerprint

Peptide YY
Neuropeptide Y
Ion Transport
Jejunum
Ligands
Haloperidol
Chlorisondamine
Ganglionic Blockers
igmesine
Sulpiride
Yohimbine
Prazosin
Guanidine
Tetrodotoxin
Opioid Receptors
Naloxone
Neuropeptides
Ganglia
Adrenergic Receptors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum. / Riviere, P. J M; Rao, R. K.; Pascaud, X.; Junien, J. L.; Porreca, Frank.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 264, No. 3, 1993, p. 1268-1274.

Research output: Contribution to journalArticle

Riviere, P. J M ; Rao, R. K. ; Pascaud, X. ; Junien, J. L. ; Porreca, Frank. / Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum. In: Journal of Pharmacology and Experimental Therapeutics. 1993 ; Vol. 264, No. 3. pp. 1268-1274.
@article{34d9f974b09f4d21bcf3a89029974fb3,
title = "Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum",
abstract = "The effects of putative σ ligands and two neuropeptides on intestinal ion transport were evaluated in isolated sheets of whole mouse jejunum mounted in Ussing flux chambers. Serosal administration of neuropeptide Y (NPY), peptide YY (PYY), (+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1- ylamine hydrochloride (JO 1784), di(ortho-tolyl) guanidine (DTG) and (+)- or (-)-N-allyl-normetazocine (NANM) produced concentration-related decreases in short-circuit current (I(sc)) without changes in tissue conductance. Although NPY and PYY were active in nanomolar concentrations, JO 1784, DTG and (+)- and (-)-NANM were active in micromolar concentrations; the rank order of potency in inhibiting I(sc) was PYY > NPY >> JO 1784 = (-)-N- cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1-ylamine hydrochloride > DTG > (+)-NANM = (-)-NANM. Serosal application of tetrodotoxin effectively blocked the decrease in I(sc) associated with all of the ligands tested. The activity of the serosally applied ligands was blocked by prior application of chlorisondamine, a ganglionic blocker. The effects of JO 1784 and NPY were evaluated using antagonists of several receptor types. Although application of serosal haloperidol had no effect alone up to concentrations of 1 μM, this compound produced a rightward displacement in both the NPY and JO 1784 concentration-effect curves. In contrast, sulpiride, SCH-23390, naloxone, yohimbine and prazosin failed to antagonize the effects of NPY or JO 1784. Application of NPY and JO 1784 on the mucosal side of intact jejunum showed that both compounds maintained activity, though the potency of each was considerably reduced compared to serosal administration. Finally, the activity of both NPY and JO 1784 was greatly reduced in a jejunal preparation physically stripped of the enteric ganglia and muscularis externa (i.e., mucosal preparation). The data indicate that putative σ ligands and NPY and PYY produce a concentration-related and haloperidol- sensitive reduction in I(sc), which is mediated via actions on nerves, and that these effects are mediated mainly through preganglionic sites. Furthermore, the insensitivity of the responses of JO 1784 and NPY to antagonists at opioid, dopaminergic or adrenergic receptors suggests that the effects of NPY and JO 1784 may be associated with a putative σ site. These data suggest that a novel application of potential therapeutic interest will be the development of σ ligands for the investigation and treatment of gastrointestinal disorders.",
author = "Riviere, {P. J M} and Rao, {R. K.} and X. Pascaud and Junien, {J. L.} and Frank Porreca",
year = "1993",
language = "English (US)",
volume = "264",
pages = "1268--1274",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum

AU - Riviere, P. J M

AU - Rao, R. K.

AU - Pascaud, X.

AU - Junien, J. L.

AU - Porreca, Frank

PY - 1993

Y1 - 1993

N2 - The effects of putative σ ligands and two neuropeptides on intestinal ion transport were evaluated in isolated sheets of whole mouse jejunum mounted in Ussing flux chambers. Serosal administration of neuropeptide Y (NPY), peptide YY (PYY), (+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1- ylamine hydrochloride (JO 1784), di(ortho-tolyl) guanidine (DTG) and (+)- or (-)-N-allyl-normetazocine (NANM) produced concentration-related decreases in short-circuit current (I(sc)) without changes in tissue conductance. Although NPY and PYY were active in nanomolar concentrations, JO 1784, DTG and (+)- and (-)-NANM were active in micromolar concentrations; the rank order of potency in inhibiting I(sc) was PYY > NPY >> JO 1784 = (-)-N- cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1-ylamine hydrochloride > DTG > (+)-NANM = (-)-NANM. Serosal application of tetrodotoxin effectively blocked the decrease in I(sc) associated with all of the ligands tested. The activity of the serosally applied ligands was blocked by prior application of chlorisondamine, a ganglionic blocker. The effects of JO 1784 and NPY were evaluated using antagonists of several receptor types. Although application of serosal haloperidol had no effect alone up to concentrations of 1 μM, this compound produced a rightward displacement in both the NPY and JO 1784 concentration-effect curves. In contrast, sulpiride, SCH-23390, naloxone, yohimbine and prazosin failed to antagonize the effects of NPY or JO 1784. Application of NPY and JO 1784 on the mucosal side of intact jejunum showed that both compounds maintained activity, though the potency of each was considerably reduced compared to serosal administration. Finally, the activity of both NPY and JO 1784 was greatly reduced in a jejunal preparation physically stripped of the enteric ganglia and muscularis externa (i.e., mucosal preparation). The data indicate that putative σ ligands and NPY and PYY produce a concentration-related and haloperidol- sensitive reduction in I(sc), which is mediated via actions on nerves, and that these effects are mediated mainly through preganglionic sites. Furthermore, the insensitivity of the responses of JO 1784 and NPY to antagonists at opioid, dopaminergic or adrenergic receptors suggests that the effects of NPY and JO 1784 may be associated with a putative σ site. These data suggest that a novel application of potential therapeutic interest will be the development of σ ligands for the investigation and treatment of gastrointestinal disorders.

AB - The effects of putative σ ligands and two neuropeptides on intestinal ion transport were evaluated in isolated sheets of whole mouse jejunum mounted in Ussing flux chambers. Serosal administration of neuropeptide Y (NPY), peptide YY (PYY), (+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1- ylamine hydrochloride (JO 1784), di(ortho-tolyl) guanidine (DTG) and (+)- or (-)-N-allyl-normetazocine (NANM) produced concentration-related decreases in short-circuit current (I(sc)) without changes in tissue conductance. Although NPY and PYY were active in nanomolar concentrations, JO 1784, DTG and (+)- and (-)-NANM were active in micromolar concentrations; the rank order of potency in inhibiting I(sc) was PYY > NPY >> JO 1784 = (-)-N- cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1-ylamine hydrochloride > DTG > (+)-NANM = (-)-NANM. Serosal application of tetrodotoxin effectively blocked the decrease in I(sc) associated with all of the ligands tested. The activity of the serosally applied ligands was blocked by prior application of chlorisondamine, a ganglionic blocker. The effects of JO 1784 and NPY were evaluated using antagonists of several receptor types. Although application of serosal haloperidol had no effect alone up to concentrations of 1 μM, this compound produced a rightward displacement in both the NPY and JO 1784 concentration-effect curves. In contrast, sulpiride, SCH-23390, naloxone, yohimbine and prazosin failed to antagonize the effects of NPY or JO 1784. Application of NPY and JO 1784 on the mucosal side of intact jejunum showed that both compounds maintained activity, though the potency of each was considerably reduced compared to serosal administration. Finally, the activity of both NPY and JO 1784 was greatly reduced in a jejunal preparation physically stripped of the enteric ganglia and muscularis externa (i.e., mucosal preparation). The data indicate that putative σ ligands and NPY and PYY produce a concentration-related and haloperidol- sensitive reduction in I(sc), which is mediated via actions on nerves, and that these effects are mediated mainly through preganglionic sites. Furthermore, the insensitivity of the responses of JO 1784 and NPY to antagonists at opioid, dopaminergic or adrenergic receptors suggests that the effects of NPY and JO 1784 may be associated with a putative σ site. These data suggest that a novel application of potential therapeutic interest will be the development of σ ligands for the investigation and treatment of gastrointestinal disorders.

UR - http://www.scopus.com/inward/record.url?scp=0027491704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027491704&partnerID=8YFLogxK

M3 - Article

C2 - 8450462

AN - SCOPUS:0027491704

VL - 264

SP - 1268

EP - 1274

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -